Cyto365 and the EIC Accelerator: A Valve Against Drug Mix-Ups

Cyto365, a Swedish medtech company led by CEO Micael Törnblom, makes RondelO, a stopcock for intravenous infusion sets that lets nurses give up to six drugs one at a time, with saline in between, through a single turn valve. Its EIC application said RondelO "solves the problem of serious side effects caused by drug incompatibility by eliminating human error and unwanted parallel infusion", and could reduce nurses' exposure to hazardous drugs, according to CORDIS.

The European Innovation Council granted €1,941,782 towards a €2.77 million project from November 2022 to April 2025; the application consultant GAEU put the whole blended award at €3.9 million. The final report says the project was designed to cut the cost of goods and automate production so large infusion-set makers would adopt RondelO. It built a multi-cavity injection mould that "reduced the COGS drastically", automated assembly with in-line quality checks and a unique QR code on each valve at "1 RondelO per second", and a modular cleanroom. It also "supported the development of a range of Final Device IV-sets with certification".

Where Cyto365 Stands Now

A company profile on the life-sciences database Gosset says RondelO has CE marking under the Medical Device Regulation, that the company holds more than 100 patents, and lists distribution partners in the US, Brazil, several European countries, Taiwan and the Nordics. Cyto365 is listed as an exhibitor at the COMPAMED 2026 trade fair. No bankruptcy or liquidation appears in Swedish listings. When checked for this article, both the company's websites, cyto365.com and rondelo.io, showed their hosting provider's "blocked page" notice.

The Device: One Drug at a Time

Mixing incompatible drugs in an IV line can cause severe reactions. RondelO's two-part plastic turn valve physically allows only one inlet to flow at once. Nurses connect all drug lines at the start, which the company says can reduce their exposure to hazardous cancer drugs when the whole set is discarded after use. The valve housing is moulded from a co-polyester chosen to resist oncology drugs.

What the EIC Project Promised, and What CORDIS Shows

The project was about making RondelO cheap and scalable enough for large infusion-set makers to adopt. The report documents the mould, automation and cleanroom, and certified IV-sets. It names no customers or licensing partners, and says only that early market communications with large players were positive. CORDIS lists the project as closed.

1. Lower-cost mouldDeliveredMulti-cavity tool.
2. Automated assemblyDelivered1 unit a second.
3. Certified IV-setsDeliveredPer report.
4. Adoption by large makersUnverifiedNo deal named.

The Money

The CORDIS grant of €1.94 million is half of the €3.9 million award GAEU announced; the rest would be EIC Fund equity. No investment by the EIC Fund or any private round has been announced. Cyto365's revenue and results are filed in Sweden but could not be retrieved for this article.

What Cannot Be Checked

Why Europe Should Care

Mixing incompatible drugs can cause severe adverse events, the report says, and nurses handle hazardous drugs daily. A simple mechanical fix built in Sweden could help. The EIC funded its production line; the evidence that hospitals and major suppliers are adopting it is not yet public.

The Verdict

Cyto365 and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.